A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to ABT-335 and Rosuvastatin Monotherapy in Subjects With Type IIa and IIb Dyslipidemia.

Trial Profile

A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to ABT-335 and Rosuvastatin Monotherapy in Subjects With Type IIa and IIb Dyslipidemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Oct 2012

At a glance

  • Drugs Rosuvastatin/choline fenofibrate (Primary) ; Choline fenofibrate; Rosuvastatin
  • Indications Dyslipidaemias
  • Focus Registrational; Therapeutic Use
  • Sponsors Abbott Laboratories; AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Jul 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 29 Mar 2009 Primary endpoint 'High density lipoprotein cholesterol level' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top